美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

AgomAb Therapeutics

13.85

-0.0600-0.43%

成交量：3.49万

成交额：48.00万

市值：6.75亿

市盈率：0.00

高：14.17

开：14.13

低：13.36

收：13.91

52周最高：17.45

52周最低：12.66

股本：4,873.68万

流通股本：1,250.00万

量比：0.42

换手率：0.28%

股息：- -

股息率：- -

每股收益(TTM):-3,391.5288

每股收益(LYR):-2,395.7345

净资产收益率：--

总资产收益率：--

市净率：-3.87

市盈率(LYR):-0.01

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

AgomAb Therapeutics

交易所：

NASDAQ

成立时间：

2017

员工人数：

62

公司地址：

Posthoflei 1/6,Antwerp,Antwerp,Belgium

官网：

http://www.agomab.com

邮编：

2600

电话：

传真：

- -

简介：

AgomAb Therapeutics NV最初于2017年4月13日根据比利时法律注册成立，是一家比利时私人有限责任公司。该公司是一家临床阶段的生物制药实体，致力于开发针对免疫学和炎症性疾病的创新疾病改善疗法，特别专注于存在重大未满足医疗需求的慢性纤维化疾病。其候选产品旨在针对既定途径，并使用经过验证的模式来增强疗效，同时最大限度地减少全身毒性，从而解决先前治疗的局限性。其使命是创造不仅能解决纤维化，还能恢复器官功能的疗法，让患者过上更充实、更健康的生活。

董事

名称

职位

David Epstein

Chairman of the Board

Tim Knotner

Chief Executive Officer and Executive Director

Angelika Jahreis

Non-Executive Director

Colin Bond

Non-Executive Director

Felice Verduyn van Weegen

Non-Executive Director

Ohad Hammer

Non-Executive Director

股东

名称

职位

Tim Knotner

Chief Executive Officer and Executive Director

Pierre Kemula

Chief Financial Officer

Andrea Sáez

Chief Development Officer

Ellen Lefever

General Counsel

Paul van der Horst

Chief Business Officer

Philippe Wiesel

Chief Medical Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AGMB/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":13.85,"timestamp":1773430231154,"preClose":13.91,"halted":0,"volume":34870,"delay":0,"changeRate":-0.00431344356578005,"floatShares":12500000,"shares":48736779,"eps":-3391.5288,"marketStatus":"交易中","change":-0.06,"latestTime":"03-13 15:31:10 EDT","open":14.13,"high":14.17,"low":13.36,"amount":480031.2297,"amplitude":0.058231,"askPrice":14.07,"askSize":30,"bidPrice":13.83,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3391.5288,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773432000000},"marketStatusCode":2,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":13.91,"postHourTrading":{"tag":"盘后","latestPrice":13.91,"preClose":13.91,"latestTime":"16:10 EDT","volume":2,"amount":27.82,"timestamp":1773346204743,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.418882},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":12500000,"roa":"--","roe":"--","lyrEps":-2395.734548,"volumeRatio":0.418882,"shares":48736779,"dividePrice":0,"high":14.17,"amplitude":0.058231,"preClose":13.91,"low":13.36,"week52Low":12.66,"pbRate":"-3.87","week52High":17.4528,"institutionHeld":0,"latestPrice":13.85,"committee":0.538462,"eps":-3391.5288,"divideRate":0,"volume":34870,"delay":0,"ttmEps":-3391.5288,"open":14.13,"prevYearClose":16,"prevWeekClose":13.62,"prevMonthClose":16.02,"prevQuarterClose":16,"fiveDayClose":13.62,"twentyDayClose":15.66,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1773201600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-03-12","current":-0.004143,"percent":0.956522,"low":-14.725744,"twenty":-14.295509,"median":-13.811207,"eighty":-13.017889,"high":-12.375764,"avg":-13.67016,"sd":0.671411,"marketCap":661358091},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-12","current":-12.400375,"twenty":-14.295509,"median":-13.811207,"eighty":-13.017889,"marketCap":661358091}],"updateTime":1773416379089},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":563168576,"yearFounded":2017,"employeeNum":62,"address":"Posthoflei 1/6,Antwerp,Antwerp,Belgium","zipCode":"2600","officePhone":"32 3 318 91 70"},"stockCompanyDetail":{"websiteUrl":"http://www.agomab.com","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.1055},{"period":"3month","weight":-0.1306},{"period":"ytd","weight":-0.1306}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AgomAb Therapeutics NV最初于2017年4月13日根据比利时法律注册成立，是一家比利时私人有限责任公司。该公司是一家临床阶段的生物制药实体，致力于开发针对免疫学和炎症性疾病的创新疾病改善疗法，特别专注于存在重大未满足医疗需求的慢性纤维化疾病。其候选产品旨在针对既定途径，并使用经过验证的模式来增强疗效，同时最大限度地减少全身毒性，从而解决先前治疗的局限性。其使命是创造不仅能解决纤维化，还能恢复器官功能的疗法，让患者过上更充实、更健康的生活。","exchange":"NASDAQ","name":"AgomAb Therapeutics","nameEN":"AgomAb Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":{"directors":[{"name":"David Epstein","position":"Chairman of the Board"},{"name":"Tim Knotner","position":"Chief Executive Officer and Executive Director"},{"name":"Angelika Jahreis","position":"Non-Executive Director"},{"name":"Colin Bond","position":"Non-Executive Director"},{"name":"Felice Verduyn van Weegen","position":"Non-Executive Director"},{"name":"Ohad Hammer","position":"Non-Executive Director"}],"executives":[{"name":"Tim Knotner","position":"Chief Executive Officer and Executive Director"},{"name":"Pierre Kemula","position":"Chief Financial Officer"},{"name":"Andrea Sáez","position":"Chief Development Officer"},{"name":"Ellen Lefever","position":"General Counsel"},{"name":"Paul van der Horst","position":"Chief Business Officer"},{"name":"Philippe Wiesel","position":"Chief Medical Officer"}]}}}